IBDEI222 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32806,1,4,0)
 ;;=4^H40.61X0
 ;;^UTILITY(U,$J,358.3,32806,2)
 ;;=^5005906
 ;;^UTILITY(U,$J,358.3,32807,0)
 ;;=H40.61X1^^128^1670^48
 ;;^UTILITY(U,$J,358.3,32807,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32807,1,3,0)
 ;;=3^GLU 2nd to Drugs,OD,Mild Stage
 ;;^UTILITY(U,$J,358.3,32807,1,4,0)
 ;;=4^H40.61X1
 ;;^UTILITY(U,$J,358.3,32807,2)
 ;;=^5005907
 ;;^UTILITY(U,$J,358.3,32808,0)
 ;;=H40.61X2^^128^1670^49
 ;;^UTILITY(U,$J,358.3,32808,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32808,1,3,0)
 ;;=3^GLU 2nd to Drugs,OD,Moderate Stage
 ;;^UTILITY(U,$J,358.3,32808,1,4,0)
 ;;=4^H40.61X2
 ;;^UTILITY(U,$J,358.3,32808,2)
 ;;=^5005908
 ;;^UTILITY(U,$J,358.3,32809,0)
 ;;=H40.61X3^^128^1670^50
 ;;^UTILITY(U,$J,358.3,32809,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32809,1,3,0)
 ;;=3^GLU 2nd to Drugs,OD,Severe Stage
 ;;^UTILITY(U,$J,358.3,32809,1,4,0)
 ;;=4^H40.61X3
 ;;^UTILITY(U,$J,358.3,32809,2)
 ;;=^5133509
 ;;^UTILITY(U,$J,358.3,32810,0)
 ;;=H40.61X4^^128^1670^51
 ;;^UTILITY(U,$J,358.3,32810,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32810,1,3,0)
 ;;=3^GLU 2nd to Drugs,OD,Indeterminate Stage
 ;;^UTILITY(U,$J,358.3,32810,1,4,0)
 ;;=4^H40.61X4
 ;;^UTILITY(U,$J,358.3,32810,2)
 ;;=^5005909
 ;;^UTILITY(U,$J,358.3,32811,0)
 ;;=H40.813^^128^1670^64
 ;;^UTILITY(U,$J,358.3,32811,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32811,1,3,0)
 ;;=3^GLC w/ Increased Episcleral Venous Pressure,OU
 ;;^UTILITY(U,$J,358.3,32811,1,4,0)
 ;;=4^H40.813
 ;;^UTILITY(U,$J,358.3,32811,2)
 ;;=^5005921
 ;;^UTILITY(U,$J,358.3,32812,0)
 ;;=H40.811^^128^1670^62
 ;;^UTILITY(U,$J,358.3,32812,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32812,1,3,0)
 ;;=3^GLC w/ Increased Episcleral Venous Pressure,OD
 ;;^UTILITY(U,$J,358.3,32812,1,4,0)
 ;;=4^H40.811
 ;;^UTILITY(U,$J,358.3,32812,2)
 ;;=^5005919
 ;;^UTILITY(U,$J,358.3,32813,0)
 ;;=H40.812^^128^1670^63
 ;;^UTILITY(U,$J,358.3,32813,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32813,1,3,0)
 ;;=3^GLC w/ Increased Episcleral Venous Pressure,OS
 ;;^UTILITY(U,$J,358.3,32813,1,4,0)
 ;;=4^H40.812
 ;;^UTILITY(U,$J,358.3,32813,2)
 ;;=^5005920
 ;;^UTILITY(U,$J,358.3,32814,0)
 ;;=H40.823^^128^1670^67
 ;;^UTILITY(U,$J,358.3,32814,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32814,1,3,0)
 ;;=3^Hypersecretion GLC,OU
 ;;^UTILITY(U,$J,358.3,32814,1,4,0)
 ;;=4^H40.823
 ;;^UTILITY(U,$J,358.3,32814,2)
 ;;=^5005925
 ;;^UTILITY(U,$J,358.3,32815,0)
 ;;=H40.821^^128^1670^65
 ;;^UTILITY(U,$J,358.3,32815,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32815,1,3,0)
 ;;=3^Hypersecretion GLC,OD
 ;;^UTILITY(U,$J,358.3,32815,1,4,0)
 ;;=4^H40.821
 ;;^UTILITY(U,$J,358.3,32815,2)
 ;;=^5005923
 ;;^UTILITY(U,$J,358.3,32816,0)
 ;;=H40.822^^128^1670^66
 ;;^UTILITY(U,$J,358.3,32816,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32816,1,3,0)
 ;;=3^Hypersecretion GLC,OS
 ;;^UTILITY(U,$J,358.3,32816,1,4,0)
 ;;=4^H40.822
 ;;^UTILITY(U,$J,358.3,32816,2)
 ;;=^5005924
 ;;^UTILITY(U,$J,358.3,32817,0)
 ;;=H40.43X0^^128^1670^27
 ;;^UTILITY(U,$J,358.3,32817,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32817,1,3,0)
 ;;=3^Inflam GLC,OU,Stage Unspec
 ;;^UTILITY(U,$J,358.3,32817,1,4,0)
 ;;=4^H40.43X0
 ;;^UTILITY(U,$J,358.3,32817,2)
 ;;=^5005878
 ;;^UTILITY(U,$J,358.3,32818,0)
 ;;=H40.43X1^^128^1670^28
 ;;^UTILITY(U,$J,358.3,32818,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32818,1,3,0)
 ;;=3^Inflam GLC,OU,Mild Stage
 ;;^UTILITY(U,$J,358.3,32818,1,4,0)
 ;;=4^H40.43X1
